Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejca.2021.01.046 http://scihub22266oqcxt.onion/10.1016/j.ejca.2021.01.046 33770576!7904467!33770576     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Cancer 2021 ; 148 (ä): 316-327 Nephropedia Template TP {{tp|p=33770576|t=2021. SARS-CoV-2 vaccines for cancer patients: a call to action |pdf=|usr=}}{{33770576}} gab.com Text SARS-CoV-2 vaccines for cancer patients: a call to action JO: Eur J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=33770576 #FOAvip Coronavirus disease 2019 (COVID-19) has affected more than 96 million people worldwide, leading the World Health Organization (WHO) to declare a pandemic in March 2020. Although an optimal medical treatment of COVID-19 remains uncertain, an unprecedented global effort to develop an effective vaccine hopes to restore pre-pandemic conditions. Since cancer patients as a group have been shown to be at a higher risk of severe COVID-19, the development of safe and effective vaccines is crucial. However, cancer patients may be underrepresented in ongoing phase 3 randomised clinical trials investigating COVID-19 vaccines. Therefore, we encourage stakeholders to provide real-time data about the characteristics of recruited participants, including clearly identifiable subgroups, like cancer patients, with sample sizes large enough to determine safety and efficacy. Moreover, we envisage a prompt implementation of suitable registries for pharmacovigilance reporting, in order to monitor the effects of COVID-19 vaccines and immunisation rates in patients with cancer. That said, data extrapolation from other vaccine trials (e.g. anti-influenza virus) showed a favourable safety and efficacy profile for cancer patients. On the basis of the evidence discussed, we believe that the benefits of the vaccination outweigh the risks. Consequently, healthcare authorities should prioritise vaccinations for cancer patients, with the time-point of administration agreed on a case-by-case basis. In this regard, the American Society of Clinical Oncology and the European Society of Medical Oncology are advocating for cancer patients a high priority status, in the hope of attenuating the consequences of the pandemic in this particularly vulnerable population. Twit Text FOAVip SARS-CoV-2 vaccines for cancer patients: a call to action ????Eur J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=33770576 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33770576 #FOAvip English Wikipedia <ref>{{Cite pmid|33770576}}</ref> SARS-CoV-2 vaccines for cancer patients: a call to action #MMPMID33770576 Corti C; Crimini E; Tarantino P; Pravettoni G; Eggermont AMM; Delaloge S; Curigliano G Eur J Cancer 2021[May]; 148 (ä): 316-327 PMID33770576show ga Coronavirus disease 2019 (COVID-19) has affected more than 96 million people worldwide, leading the World Health Organization (WHO) to declare a pandemic in March 2020. Although an optimal medical treatment of COVID-19 remains uncertain, an unprecedented global effort to develop an effective vaccine hopes to restore pre-pandemic conditions. Since cancer patients as a group have been shown to be at a higher risk of severe COVID-19, the development of safe and effective vaccines is crucial. However, cancer patients may be underrepresented in ongoing phase 3 randomised clinical trials investigating COVID-19 vaccines. Therefore, we encourage stakeholders to provide real-time data about the characteristics of recruited participants, including clearly identifiable subgroups, like cancer patients, with sample sizes large enough to determine safety and efficacy. Moreover, we envisage a prompt implementation of suitable registries for pharmacovigilance reporting, in order to monitor the effects of COVID-19 vaccines and immunisation rates in patients with cancer. That said, data extrapolation from other vaccine trials (e.g. anti-influenza virus) showed a favourable safety and efficacy profile for cancer patients. On the basis of the evidence discussed, we believe that the benefits of the vaccination outweigh the risks. Consequently, healthcare authorities should prioritise vaccinations for cancer patients, with the time-point of administration agreed on a case-by-case basis. In this regard, the American Society of Clinical Oncology and the European Society of Medical Oncology are advocating for cancer patients a high priority status, in the hope of attenuating the consequences of the pandemic in this particularly vulnerable population. |2019-nCoV Vaccine mRNA-1273[MESH] |Ad26COVS1[MESH] |BNT162 Vaccine[MESH] |COVID-19 Vaccines/*therapeutic use[MESH] |COVID-19/complications/*prevention & control[MESH] |ChAdOx1 nCoV-19[MESH] |Drug Approval[MESH] |Drug Development[MESH] |Humans[MESH] |Neoplasms/complications/*therapy[MESH] |SARS-CoV-2[MESH] |Vaccines, Attenuated[MESH] |Vaccines, Inactivated[MESH] |Vaccines, Subunit[MESH] |Vaccines, Synthetic[MESH] |Vaccines, Virus-Like Particle[MESH]SARS-CoV-2 vaccines for cancer patients: a call to action (epmc).pdf DeepDyve Pubget Overpricing